# Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

> **NCT05008913** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 2 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** [14C]Adavosertib

## Key facts

- **NCT ID:** NCT05008913
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-01
- **Primary completion:** 2021-11-16
- **Final completion:** 2021-11-16
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study terminated because the clinical development programme for Adavosertib has been discontinued
- **Last updated:** 2022-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05008913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05008913, "Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05008913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*